Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2020 Conference Call
February 12 2020 - 8:30AM
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”)
(TSXV: MDP, OTCQB: PDDPF) today announced that it plans to
host a conference call at 8:00 AM Eastern Time on Wednesday,
February 19, 2020 to discuss the Company’s financial results for
the third quarter ended December 31, 2019, as well as the
Company’s corporate progress and other developments. The Company
expects to file its financial statements along with its MD&A
post market on February 18, 2020.
The conference call will be available via
telephone by dialing toll free 844-369-8770 for Canadian and U.S.
callers or +1 862-298-0840 for international callers, or on the
Company’s Investor Events section of the website:
https://www.medexus.com/news-media/events
A webcast replay will be available on the
Company’s Investor Events section of the website
(https://www.medexus.com/news-media/events) through May 19, 2020. A
telephone replay of the call will be available approximately one
hour following the call, through February 26, 2020, and can be
accessed by dialing 877-481-4010 for Canadian and U.S. callers or
+1 919-882-2331 for international callers and entering conference
ID: 33141.
About Medexus Pharmaceuticals Inc.Medexus is a
leading specialty pharmaceutical company with a strong North
American commercial platform. The Company’s vision is to provide
the best healthcare products to healthcare professionals and
patients, through our core values of Quality, Innovation, Customer
Service and Teamwork. Medexus Pharmaceuticals is focused on
the therapeutic areas of auto-immune disease and pediatrics. The
leading products are Rasuvo and Metoject, a unique formulation of
methotrexate (auto-pen and pre-filled syringe) designed to treat
rheumatoid arthritis and other auto-immune diseases; and Rupall, an
innovative allergy medication with a unique mode of action.
For more information, please
contact: Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations
(U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020Email: mdp@crescendo-ir.com
Investor Relations
(Canada):Frank CandidoDirect Financial Strategies
and Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexus.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024